About this Research Topic
Patients with advanced NSCLC who progress after chemo-immunotherapy, administered either concurrently or sequentially, have limited treatment options. Second-line chemotherapy with docetaxel, administered either alone or in combination with ramucirumab offers modest clinical outcomes. Recent advances in the elucidation of the molecular biology of the disease have led to the identification of molecular pathways of resistance that could be exploited therapeutically in an effort to improve outcomes by overcoming resistance to immunotherapy and chemotherapy
The scope of the current Research Topic is to present the new treatment strategies used to overcome resistance to chemo-immunotherapy by identification of the molecular mechanisms of resistance and exploiting therapeutically with new combinations of agents targeting distinct molecular pathways.
Examples:
· Combinations of immune checkpoint inhibitors (ie anti-PD-(L)1 and anti-CTLA4)
· Combinations of immune checkpoint inhibitors with tyrosine kinase inhibitors
· New monoclonal antibodies (ie anti-CEACAM5, anti-TIGIT, Anti-LAG3)
· Bispecific antibodies, novel pathways
· New molecular agents for SCLC, mesothelioma, thymic carcinoma
Keywords: resistance, chemotherapy, immunotherapy, NSCLC, SCLC, Mesothelioma, Thoracic Oncology
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.